N@N

Entest BioMedical Files Grant Application With the National Heart, Lung and Blood Institute for Development of the Company's EN

^{Published on 2009-12-30 05:40:17 - Market Wire}
 

SAN DIEGO, CA--(Marketwire - December 30, 2009) - Entest Biomedical Inc. (OTCBB: [ ENTB ]) announced that it has filed a grant application with the National Heart, Lung and Blood Institute (NHLBI) for the development of the Company's ENT-576 Laser Device to be used in treating Chronic Obstructive Pulmonary Disease (COPD). Should the Company's application be approved, the NHLBI could provide grant funding of approximately $500,000 to Entest.

Grant funding will accelerate the process of developing the Company's patent pending laser-based therapeutic platform to enhance efficacy levels in stem cell therapy among patients with COPD. Entest's patent-pending approach revolves around the use of the patient's own stem cells in combination with specific laser wavelengths in repairing damaged lung tissue of patients with COPD.

David Koos, Chairman & CEO of Entest Biomedical, stated: "We are excited about the outlook for our Laser Device (ENT-576). The Entest approach involves administration of an FDA-approved drug that releases stem cells from the bone marrow followed by administration of optimized laser energy into lung tissue. We believe this treatment to be relatively non-invasive compared to other stem cell therapies involving cell extraction and manipulation."

Both components of the ENT-576 product have previously been clinically used for other indications. The Company believes it can get this technology to market quickly -- making regenerative therapy finally available to COPD patients.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: [ ENTB ]) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: [ BMSN ]). The Company is involved with the development of stem cell therapy treatments for COPD, immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses.

Follow the Company's progress on Twitter:

[ http://twitter.com/Entest_BioMed ]

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.